Covovax gets WHO emergency use nod

Covovax gets WHO emergency use nod

18.12.2021

The WHO on Friday issued emergency use listing for anti-Covid vaccine Covovax, produced by the Serum Institute of India under licence from Novavax, expanding the basket of jabs validated by the global health body against the viral disease. CEO Adar Poonawalla had said earlier that SII planned to launch Covovax in the next six months. He had stated that Covovax, which is under trial, would offer protection to children down to three years. Covovax is still awaiting emergency use authorisation from DCGI. The Technical Advisory Group for Emergency Use Listing (TAG-EUL) has determined that the benefits of the vaccine far outweigh any risks, and that the vaccine can be used globally. AGENCIES

Min: 28 in TN show Omicron indication

At least 28 people who arrived in TN from both ‘high-risk’ and ‘non-risk’ countries have tested Covid-19 positive along with S-gene drop, raising the suspicion of Omicron infection, health minister Ma Subramanian said on Friday. Their samples have been sent for genome sequencing, he said. More than 14,800 passengers, including 12,767 from ‘high-risk’ countries, had underwent RTPCR tests in two weeks and 70 had tested positive. Centre’s nod has been sought to make seven-day home isolation and RTPCR test must for all foreign passengers entering the state, the minister said.